Sarcoma
Volume 2008 (2008), Article ID 412503, 7 pages
doi:10.1155/2008/412503
Clinical Study

Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma

Michelle S. Boyar,1 Mary Hesdorffer,2 Mary Louise Keohan,1 Zhezhen Jin,3 and Robert N. Taub4

1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
2Mesothelioma Applied Research Foundation, Santa Barbara, CA 93190, USA
3Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY 10032, USA
4Division of Medical Oncology, Department of Medicine, Columbia University Medical Center, Herbert Irving Pavilion, 161 Fort Washington Avenue, New York, NY 10032, USA

Received 6 May 2008; Revised 17 August 2008; Accepted 29 September 2008

Academic Editor: Charles Scoggins

Copyright © 2008 Michelle S. Boyar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, T. Murray, E. Ward, et al., “Cancer statistics, 2005,” CA: A Cancer Journal for Clinicians, vol. 55, no. 1, pp. 10–30, 2005. View at Publisher · View at Google Scholar
  2. J. H. Edmonson, L. M. Ryan, R. H. Blum, et al., “Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas,” Journal of Clinical Oncology, vol. 11, no. 7, pp. 1269–1275, 1993.
  3. K. H. Antman, L. Ryan, A. Elias, D. Sherman, and H. E. Grier, “Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma,” Journal of Clinical Oncology, vol. 7, no. 1, pp. 126–131, 1989.
  4. J. A. Gottlieb, R. S. Benjamin, L. H. Baker, et al., “Role of DTIC (NSC-84538) in the chemotherapy of sarcomas,” Cancer Treatment Reports, vol. 60, no. 2, pp. 199–203, 1976.
  5. E. C. Borden, D. A. Amato, C. Rosenbaum, et al., “Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas,” Journal of Clinical Oncology, vol. 5, no. 6, pp. 840–850, 1987.
  6. G. D. Demetri, M. von Mehren, C. D. Blanke, et al., “Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors,” The New England Journal of Medicine, vol. 347, no. 7, pp. 472–480, 2002. View at Publisher · View at Google Scholar · View at PubMed
  7. M. F. Brennan, E. S. Casper, and L. B. Harrison, “Soft tissue sarcoma,” in Cancer Principles and Practice of Oncology, V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg, Eds., pp. 1738–1788, Lippincott-Raven, Philadelphia, Pa, USA, 5th edition, 1997.
  8. L. L. H. Tsang, C. P. Quarterman, A. Gescher, and J. A. Slack, “Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide,” Cancer Chemotherapy and Pharmacology, vol. 27, no. 5, pp. 342–346, 1991. View at Publisher · View at Google Scholar
  9. M. F. G. Stevens and E. S. Newlands, “From triazines and triazenes to temozolomide,” European Journal of Cancer Part A, vol. 29, no. 7, pp. 1045–1047, 1993. View at Publisher · View at Google Scholar
  10. M. Bower, E. S. Newlands, N. M. Bleehen, et al., “Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma,” Cancer Chemotherapy and Pharmacology, vol. 40, no. 6, pp. 484–488, 1997. View at Publisher · View at Google Scholar
  11. M. R. Middleton, J. J. Grob, N. Aaronson, et al., “Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma,” Journal of Clinical Oncology, vol. 18, no. 1, pp. 158–166, 2000.
  12. S. M. Talbot, M. L. Keohan, M. Hesdorffer, et al., “A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma,” Cancer, vol. 98, no. 9, pp. 1942–1946, 2003. View at Publisher · View at Google Scholar · View at PubMed
  13. J. C. Trent, J. Beach, M. A. Burgess, et al., “A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas,” Cancer, vol. 98, no. 12, pp. 2693–2699, 2003. View at Publisher · View at Google Scholar · View at PubMed
  14. P. J. Woll, I. Judson, S. M. Lee, et al., “Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group,” European Journal of Cancer, vol. 35, no. 3, pp. 410–412, 1999. View at Publisher · View at Google Scholar
  15. S. Kumar and S. V. Rajkumar, “Thalidomide and lenalidomide in the treatment of multiple myeloma,” European Journal of Cancer, vol. 42, no. 11, pp. 1612–1622, 2006. View at Publisher · View at Google Scholar · View at PubMed
  16. W.-J. Hwu, S. E. Krown, J. H. Menell, et al., “Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma,” Journal of Clinical Oncology, vol. 21, no. 17, pp. 3351–3356, 2003.
  17. M. H. Kulke, K. Stuart, P. C. Enzinger, et al., “Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors,” Journal of Clinical Oncology, vol. 24, no. 3, pp. 401–406, 2006. View at Publisher · View at Google Scholar · View at PubMed
  18. X. Garcia del Muro, A. Lopez-Pousa, J. Martin, et al., “A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the spanish group for research on sarcomas,” Cancer, vol. 104, no. 8, pp. 1706–1712, 2005. View at Publisher · View at Google Scholar · View at PubMed
  19. S. Anderson and C. Aghajanian, “Temozolomide in uterine leiomyosarcomas,” Gynecologic Oncology, vol. 98, no. 1, pp. 99–103, 2005. View at Publisher · View at Google Scholar · View at PubMed
  20. M. E. Hegi, A.-C. Diserens, T. Gorlia, et al., “MGMT gene silencing and benefit from temozolomide in glioblastoma,” The New England Journal of Medicine, vol. 352, no. 10, pp. 997–1003, 2005. View at Publisher · View at Google Scholar · View at PubMed